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Abstract
Background: The European directive on basic safety standards (Council directive 2013/
59 Euratom) mandates dosimetry-based treatment planning for radiopharmaceutical
therapies. The directive comes into operation February 2018, and the aim of a report
produced by the Internal Dosimetry Task Force of the European Association of Nuclear
Medicine is to address this aspect of the directive. A summary of the report is
presented.
Results: A brief review of five of the most common therapy procedures is included in
the current text, focused on the potential to perform patient-specific dosimetry. In the
full report, 11 different therapeutic procedures are included, allowing additional
considerations of effectiveness, references to specific literature on quantitative
imaging and dosimetry, and existing evidence for absorbed dose-effect correlations for
each treatment. Individualized treatment planning with tracer diagnostics and verification
of the absorbed doses delivered following therapy is found to be scientifically feasible for
almost all procedures investigated, using quantitative imaging and/or external
monitoring. Translation of this directive into clinical practice will have significant
implications for resource requirements.
Conclusions: Molecular radiotherapy is undergoing a significant expansion, and the
groundwork for dosimetry-based treatment planning is already in place. The mandated
individualization is likely to improve the effectiveness of the treatments, although must
be adequately resourced.
Keywords: Molecular radiotherapy, Treatment planning, Dosimetry
Background
Radiopharmaceuticals have been used for the treatment of various forms of cancer and
benign diseases since the 1940s [1, 2]. The level of radioactivity administered is primarily
fixed, sometimes adjusted by body weight, body surface area, or clinical factors. Prescrip-
tion levels for different treatments are commonly determined empirically, using similar
approaches as for chemotherapy. The term “molecular radiotherapy” (MRT) has gained
acceptance in recent years to describe the use of radiotherapeutics. Uniquely, for MRT,
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the patient-specific biodistribution can be determined by in vivo nuclear medicine im-
aging of the radiopharmaceutical, and basic biokinetics can also be monitored by external
probes. Quantitative imaging of a tracer amount of either the radiopharmaceutical or of a
companion diagnostic prior to therapy can enable the therapeutic administration to be
chosen to achieve prescribed absorbed doses to different tissues. Post-therapy imaging en-
ables the prescribed absorbed dose to be verified. Recently, the panel of mechanisms and
targets for radiopharmaceuticals has increased significantly. Together with newly available
radiotherapeutics, this has raised greater awareness of the field of molecular radiotherapy
and in combination with technical developments has also rekindled the interest for
patient-specific dosimetry in research settings and in clinical practice.
The European Council directive 2013/59/ Euratom mandates the use of dosimetry
for treatment planning and verification [3]. In Chapter VII, Medical Exposures, Article
56, it is stated that:
“For all medical exposure of patients for radiotherapeutic purposes, exposures of
target volumes shall be individually planned and their delivery appropriately verified
taking into account that doses to non-target volumes and tissues shall be as low as
reasonably achievable and consistent with the intended radiotherapeutic purpose of
the exposure.”
Furthermore, from Chapter II, Definitions, Article 4, Definition 81, it is stated that:
“‘radiotherapeutic’ means pertaining to radiotherapy, including nuclear medicine for
therapeutic purposes”.
The directive is due to come into force February 2018 and has been subject to con-
siderable debate regarding interpretation and how the requirements may be fulfilled.
Therefore, in 2015, the multidisciplinary Internal Dosimetry Task Force (IDTF) was
established by the European Association of Nuclear Medicine (EANM) to address as-
pects of the 2013/59/ Euratom directive specifically concerned with dosimetry for
MRT. The EANM IDTF consists of 17 members from Belgium, Czech Republic,
Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden, Switzerland, Turkey,
and the UK. Treatment-specific sections were drafted for 11 different categories of
therapy procedures and indications (Table 1). The aim of the group was to identify the
potential for patient-specific treatment planning and verification. While selected possi-
bilities for imaging or other measurements and dosimetric methodology are included,
no reviews regarding the optimal methods or the accuracy of the absorbed dose-effect
relationships were performed. The specific pre- and post-therapy sections are therefore
to be considered as suggested solutions and not definite guidelines. The report on the
potential and prospects for dosimetry-based treatment planning for MRT will be made
available on the EANM website. The aims of this article are to summarize the IDTF re-
port and briefly review examples of treatment-specific dosimetric planning procedures.
Summary of report
The radiopharmaceutical procedures covered in the full report are listed in Table 1,
which also displays selected post-therapy imaging and measurement methods that can
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form the basis for verification of absorbed doses delivered. Furthermore, the possibility
for administration of a tracer amount of the radiopharmaceutical itself or of a “com-
panion diagnostic” to estimate absorbed doses “up front” are indicated. Current clinical
therapy regimens vary from single administrations to multiple cycles, and prescriptions
range from the delivery of a fixed amount of radioactivity to dosimetric treatment plan-
ning. The range of current practice is reported in an IDTF survey on implementation
of dosimetry procedures in Europe [4].
In the following sections, the potential for dosimetric treatment planning are summa-
rized for five of the most common individual therapy procedures. In the full report, a
brief introduction to the disease and radiopharmaceutical is given for each procedure,
followed by a brief review of the reported effectiveness of the treatment, the potential
for quantitative imaging that underpins normal tissue and target dosimetry, and exist-
ing evidence for absorbed dose-effect correlations. The potential for personalized
dosimetry-based treatment planning is then considered. Finally, issues specific to the
Table 1 Molecular radiotherapies and possibilities for dosimetric treatment planning identified in
the report
Radiopharmaceutical Procedure Compounds used
for pre-treatment
imaging
Post-treatment imaging or
measurement methods
131I NaI Benign thyroid disease 131I NaI
124I NaI
123I NaI
Thyroid probe. Gamma
cameraa or SPECT/CT.
131I NaI Differentiated thyroid cancer (DTC)
with ablative intent and in the case of
recurrent disease
131I NaI
124I NaI
123I NaI
Gamma camera or SPECT/CT.
Whole-body probes, blood
sampling
131I mIBG Neuroblastoma in children and young
adults
131I mIBG
124I mIBG
123I mIBG
Whole-body probe for bone
marrow estimation.
Gamma camera or SPECT/CT
131I mIBG Neuroendocrine tumors in adults 131I mIBG
124I mIBG
123I mIBG
Gamma camera or SPECT/CT
177Lu DOTATATE Neuroendocrine tumors Radiolabelled
somatostatin
analogs
Gamma camera or SPECT/CT
90Y somatostatin
analogs
Adult neuroendocrine disease Analogs, as 86Y–
DOTATOC
111In-DOTATATE
Bremsstrahlung gamma
camera or SPECT/CT.
PET/CT.
89SrCl2,
153Sm-
EDTMP, 186Re-HEDP,
and 188Re-HEDP
Bone pain palliation 99mTc-MDP for
153Sm-EDTMP
Gamma camera or
SPECT/CT for
153Sm-EDTMP, 186Re-HEDP
and 188Re-HEDP
223Ra dichloride Bone metastases from castration-
resistant prostate cancer
99mTc-MDP Planar gamma camera
imaging
177Lu PSMA ligands
Metastatic castration-resistant pros
tate cancer
Analog PET
ligands
SPECT/CT
90Y microspheres Liver metastases or primary tumors 99mTc-albumin
macro aggregate
Bremsstrahlung SPECT/CT.
PET/CT.
90Y-ibritumomab
tiuxetan
Non-Hodgkin’s lymphoma 111In-
ibritumomab
tiuxetan
Bremsstrahlung gamma
camera or SPECT/CT.
PET/CT.
90Y, 32P, and 186Re
colloid, 169Er citrate
Radiosynovectomy 99mTc MDP/HDP/
HEDP and/or
99mTc-HIG
Planar Gamma camera
imaging,
# dicentric chromosomes
aGamma camera indicates both planar scintigraphy imaging and SPECT/CT imaging, if not otherwise specified
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treatment are considered along with questions that merit further investigation. For the
individual procedures included in the present summary, these have been condensed in
two paragraphs: the first presenting the therapy and current practice, followed by a sec-
ond describing the dosimetric procedures and dose-effects. Resource requirements are
reported in a separate section.
131I NaI for the treatment of differentiated thyroid cancer with ablative intent and in the
case of recurrent disease
The amount of 131I NaI activity to administer for differentiated thyroid cancer
(DTC) treatment is commonly empirically determined. Typically, a fixed activity
of 131I NaI ranging between 1.11 and 7.4 GBq is given [5]. In the case of recur-
rent disease, the administered activity may be calculated based on the absorbed
dose constraints of the normal tissue, usually red marrow as recommended in
EANM guidelines [6].
Radioiodine uptake in thyroid remnants and metastases can be determined with
gamma camera planar imaging or with SPECT/CT which can provide more accurate
quantification [7]. Camera calibrations and radiation protection measures may be
demanded due to a high photon flux [7]. PET/CT imaging can also be performed using
124I NaI, which may be advantageous for determination of remnant mass and small me-
tastases [8]. Currently, in the treatment of DTC, there are no well-established values
for absorbed doses to remnants and metastases which may be used as prescription
values. EANM guidelines recommend the calculation of red marrow absorbed doses
from whole-body and blood dosimetry [6], and a constraint of 2 Gy is considered when
using this methodology [9]. Additional organs at risk may include the lungs and salivary
glands [10–12]. Issues regarding the alteration of biodistribution can occur due to the
debated “stunning effect” for 131I NaI [13, 14] or due to prior administration of recom-
binant human thyroid-stimulating hormone (rhTSH) [15], which may have to be con-
sidered if treatment planning is performed.
131I mIBG for the treatment of neuroblastoma in children and young adults
The metaiodobenzylguanidine (mIBG) molecule structurally resembles norepinephrine
(also called noradrenaline), and tumors expressing the norepinephrine transporter show
mIBG uptake capacity. The prescription of 131I mIBG for neuroblastoma is often made
according to whole-body absorbed dose, which is related to bone marrow absorbed
dose and neutropenia [16].
If stem cell rescue is not scheduled, the main organ at risk is usually the bone mar-
row, with an absorbed dose constraint of 2 Gy [17]. An increasingly common protocol
is to deliver a whole-body absorbed dose of 4 Gy in two administrations of activity sep-
arated by 2 weeks, followed by stem cell rescue. The first administration is delivered ac-
cording to a body mass-based prescription of 444 MBq/kg [18]. The whole-body
absorbed dose can be estimated by dose-rate measurements obtained with a probe.
However, if there is bone marrow involvement, imaging is necessary to perform dosim-
etry. Quantitative imaging can be performed essentially as for 131I NaI, with the same
technical considerations [7].
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177Lu-DOTATATE for the treatment of neuroendocrine tumors
177Lu-DOTATATE is a radiolabelled somatostatin analog developed for the treatment
of patients with somatostatin receptor-positive neuroendocrine tumors. The most fre-
quent treatment protocol is currently to administer 7.4 GBq for up to four times with a
6 to 10-week interval between each administration [19]. However, protocols delivering
cycles of 7.4 GBq until a maximum prescribed absorbed dose to the kidneys and the
bone marrow is reached are under investigation [20].
Although the photon yield is relatively low, the high level of activity administered
makes quantitative gamma camera imaging of 177Lu possible [21, 22]. Late treatment-
related kidney toxicity has not been reported for patients receiving a kidney absorbed
dose over 28 Gy, a commonly used tolerance limit, indicating that this may be a con-
servative value [23]. A clear correlation between tumor absorbed doses and the re-
sponse to the treatment was reported in pancreatic neuroendocrine tumors [24].
Although it has been demonstrated that patient-specific absorbed doses for 177Lu can
be calculated and have a clinical benefit, the absorbed dose limits for normal tissue and
the desirable absorbed dose to the tumors require further investigations.
223Ra dichloride for the treatment of bone metastases from castration-resistant prostate
cancer
223Ra dichloride is an alpha-emitting radiopharmaceutical approved for the treatment
of patients with castration-resistant prostate cancer, symptomatic bone metastases, and
no known visceral metastatic disease. Being an analog to calcium, cationic radium is
taken up by areas of increased osteoblastic activity. A fractionated approach is routinely
used for the delivery of this treatment with six administrations of 55 kBq/kg body
weight.
The low yield of photons, combined with the low amount of activity administered,
makes quantitative imaging of 223Ra challenging. However, it has been demonstrated
that prolonged gamma camera imaging is feasible [25, 26] and that activity can be
quantified to within 20–50%, depending on the volume imaged. A study showed that
absorbed doses delivered to normal organs vary by an order of magnitude between in-
dividual patients [27]. Uptake of 223RaCl2 in metastases has been seen to correlate with
that of 99mTc MDP [28], demonstrating a potential for treatment planning. There is no
evidence as yet of correlations between the absorbed doses delivered and effect. Besides
developing reliable dosimetric methodology for this treatment, the relative biological ef-
fect is yet to be determined, and the short range of the alpha emissions necessitates in-
vestigations of microdosimetry and small-scale dosimetry.
90Y microspheres for the treatment of primary and metastatic liver cancer
Intra-arterial locoregional liver therapies have their rationale in the fact that liver le-
sions are fed mainly by the arterial stream, while normal parenchyma is supplied by
portal vein blood flow. At present, both 90Y glass microspheres and 90Y resin micro-
spheres are used, both licensed as medical devices to treat liver primary hepatocarci-
noma (HCC) and liver metastases [29]. Toxicity is of particular importance, as patient
death from radioembolization-induced liver disease leading to liver failure can be a
consequence of a standard treatment [30]. With current recommendations, dosimetry
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is sometimes used as a basis for treatment planning, although methods for absorbed
dose prescription vary.
Simulation scanning is performed with 99mTc-albumin macro aggregate (MAA) ad-
ministered under angiographic guidance for quantitative imaging and pre-treatment
dosimetry [29]. The permanent trapping into liver capillaries of the 99mTc MAA and of
the therapeutic 90Y microspheres allows dosimetry to be performed from only one scan
[30]. Post-therapy quantitative imaging can be performed by 90Y bremsstrahlung
SPECT or 90Y PET with suitable corrections [31, 32]. Correlations between the
absorbed doses delivered and toxicity and response have been reported both for hepa-
tocellular carcinoma [33–35] and colorectal metastases [36, 37].
Resource requirements
Implementation of dosimetry for therapy, particularly on a routine basis, has implica-
tions for infrastructure resourcing. The level of resources required will depend on the
complexity of the dosimetry procedure and will vary according to local and national
protocols and guidelines. Each procedure will have resource implications for both an
initial setup of a dosimetry service and for ongoing support.
Resources fall into categories of equipment and staff. Whole-body dosimetry may be
performed with a portable or externally mounted compensated Geiger counter which
enables multiple measurements to be made by either staff or, if necessary, possibly by
comforters and carers. Both the legal implications and the technical complexity should
be carefully considered if the latter group is to perform such measurements. Blood dos-
imetry may be derived from samples measured in a well counter. Image-based dosim-
etry requires a gamma camera or PET system that has been set up for the radionuclide
under investigation at activity levels relevant to the procedure. In addition to routine
quality control procedures, this entails determination of calibration factors for image
quantification and characterization of camera deadtime which is important for post-
therapy imaging. For each therapeutic procedure, the required number of measurement
time points (especially imaging time points) needs careful investigations as this directly
affects both the dosimetric accuracy and the resource implications. Unlike many of the
other resource requirements, this also impacts the time spent by the patients. Volume
estimation may be acquired from radiological images or, in the case of radioiodine
treatment of benign thyroid disease, from ultrasound scanning as well as from the
SPECT and PET data.
As a multidisciplinary area, a range of trained staff are necessary to provide a com-
prehensive service. These include medical physicists for image quantification and
absorbed dose calculations, nuclear medicine technologists and radiographers with ex-
perience in quantitative imaging, nuclear medicine physicians and radiologists for per-
forming or supervising volume outlining, and possibly other specialists to contribute
on patient-specific prescriptions and procedures.
Discussion
The potential for dosimetry-based treatment planning was demonstrated for all therapy
procedures, using either the same radiopharmaceutical or diagnostic analogs. Both plan-
ning and verification can be technically demanding due to various factors, including low
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activity levels in patients and/or low photon yield, image co-registration, calibration of the
system, volume definition, choice of imaging time points, and kinetic modelling. However,
extensive work has laid the foundation for individualized dosimetry of MRTs.
Absorbed dose-effect relationships have been determined for many therapy proce-
dures in single-center studies, and multicenter clinical trials are necessary to gather fur-
ther evidence and substantiate these findings. However, relevant data can be collected
by simply performing post-therapy imaging and dosimetry routinely in current practice
and by comparison of the absorbed doses delivered with response and toxicity data. For
many MRTs, a requirement for post-therapy verification may therefore represent a ra-
tional and feasible manner of initiating a dosimetry-based treatment planning program.
In conclusion, molecular radiotherapy is undergoing a significant expansion. Many
new radiotherapeutics are being introduced into the clinic and an increasing number of
patients are being treated for common as well as rare cancers. This will have a signifi-
cant effect on healthcare funding, patient management, and the logistical and scientific
challenges faced by nuclear medicine departments and their collaborators. As medicine
in general has begun to focus on personalized treatment, often accompanied by mo-
lecular imaging, this growth in radiotherapeutics offers unprecedented opportunities
for recognition, support, and significant development. Nuclear medicine combines
diagnostics and therapeutics and provides unique possibilities for personalized treat-
ment. The EANM IDTF report provides an overview of the potential and prospects for
dosimetry-based treatment planning of MRT, revealing that the groundwork is already
in place. The report focuses on the overall aspects of treatment planning, and further
work may be required to complement the status summary. Topics of interest include
the use of companion diagnostics, resource implications, the study of absorbed dose-
effect correlations, refinement of technical aspects including image quantification and
voxel-based dosimetry, biophysical considerations including biologically effective dose
(BED) calculations, education, and training. These investigations are important to en-
sure the clinical and cost-effectiveness of new radiotherapeutics, as well as for estab-
lished therapy procedures. However, MRT has the unique potential to provide patient-
specific molecular information allowing guidance for personalized treatment.
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